Journal of Pregnancy [28] S. B. Lee, A. P. Wong, K. Kanasaki et al., “Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development speciﬁcally under hypoxic conditions,” American Journal of Pathology, vol. 176, no. 2, pp. 710–720, 2010. [29] V. M. Holers, “The spectrum of complement alternative path- way-mediated diseases,” Immunological Reviews, vol. 223, no. 1, pp. 300–316, 2008. [30] H. J. Imrie, T. P. McGonigle, D. T. Y. Liu, and D. R. E. Jones, “Reduction in erythrocyte complement receptor 1 (CR1, CD35) and decay accelerating factor (DAF, CD55) during nor- mal pregnancy,” Journal of Reproductive Immunology, vol. 31, no. 3, pp. 221–227, 1996. [31] S. B. Abramson and J. P. Buyon, “Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy,” American Journal of Reproductive Immunology, vol. 28, no. 3-4, pp. 183– 187, 1992. [32] D. Sinha, M. Wells, and W. Page Faulk, “Immunological studies of human placentae: complement components in pre- eclamptic chorionic villi,” Clinical and Experimental Immunol- ogy, vol. 56, no. 1, pp. 175–184, 1984. [33] A. M. Lynch, J. R. Murphy, T. Byers et al., “Alternative comple- ment pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp. 385.e1–385.e9, 2008. [34] F. Tedesco, O. Radillo, G. Candussi, A. Nazzaro, T. E. Mollnes, and D. Pecorari, “Immunohistochemical detection of terminal complement complex and S protein in normal and pre- eclamptic placentae,” Clinical and Experimental Immunology, vol. 80, no. 2, pp. 236–240, 1990. [35] C. Labarrere and E. Mullen, “Fibrinoid and trophoblastic necrosis with massive chronic intervillositis: an extreme var- iant of villitis of unknown etiology,” American Journal of Re- productive Immunology and Microbiology, vol. 15, no. 3, pp. 85–91, 1987. [36] R. Rampersad, A. Barton, Y. Sadovsky, and D. M. Nelson, “The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro,” Placenta, vol. 29, no. 10, pp. 855–861, 2008. [37] G. Girardi, R. Bulla, J. E. Salmon, and F. Tedesco, “The com- plement system in the pathophysiology of pregnancy,” Molec- ular Immunology, vol. 43, no. 1-2, pp. 68–77, 2006. [38] F. Tedesco, G. Narchi, O. Radillo, S. Meri, S. Ferrone, and C. Betterle, “Susceptibility of human trophoblast to killing by human complement and the role of the complement reg- ulatory proteins,” Journal of Immunology, vol. 151, no. 3, pp. 1562–1570, 1993. [39] J. E. Salmon, C. Heuser, M. Triebwasser et al., “Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort,” PLoS Medicine, vol. 8, no. 3, Article ID e1001013, 2011. [40] G. Krikun, S. T. J. Huang, F. Schatz, C. Salaﬁa, C. Stocco, and C. J. Lockwood, “Thrombin activation of endometrial endo- thelial cells: a possible role in intrauterine growth restriction,” Thrombosis and Haemostasis, vol. 97, no. 2, pp. 245–253, 2007. [41] J. Hustin, J. M. Foidart, and R. Lambotte, “Maternal vascular lesions in pre-eclampsia and intrauterine growth retardation: light microscopy and immunoﬂuorescence,” Placenta, vol. 4, pp. 489–498, 1983. [42] A. T. Papageorghiou and N. Roberts, “Uterine artery Doppler screening for adverse pregnancy outcome,” Current Opinion in Obstetrics and Gynecology, vol. 17, no. 6, pp. 584–590, 2005. 5 [43] J. Procha´zkova´, R. Pilka, A. Meˇchurova´, O. Sˇimetka, P. Brych- tova´, and M. Procha´zka, “Endotelial activation markers— possibilities of their detection and clinical signiﬁcation in gynaecology and obstetric,” Ceska Gynekologie, vol. 74, no. 4, pp. 279–281, 2009. [44] B. L. Sheppard and J. Bonnar, “An ultrastructural study of utero-placental spiral arteries in hypertensive and normoten- sive pregnancy and fetal growth retardation,” British Journal of Obstetrics and Gynaecology, vol. 88, no. 7, pp. 695–705, 1981. [45] M. Levi, T. van der Poll, and H. ten Cate, “Tissue factor in in- fection and severe inﬂammation,” Seminars in Thrombosis and Hemostasis, vol. 32, pp. 33–39, 2006. [46] V. Grau, O. Stehling, H. Garn, and B. Steiniger, “Accumulating monocytes in the vasculature of rat renal allografts: pheno- type, cytokine, inducible no synthase, and tissue factor mRNA expression,” Transplantation, vol. 71, no. 1, pp. 37–46, 2001. [47] R. Tilley and N. Mackman, “Tissue factor in hemostasis and thrombosis,” Seminars in Thrombosis and Hemostasis, vol. 35, pp. 5–10, 2006. [48] H. Fei, J. A. Berliner, F. Parhami, and T. A. Drake, “Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide,” Arteriosclerosis and Thrombosis, vol. 13, no. 11, pp. 1711–1717, 1993. [49] H. Ho¨lschermann, R. M. Bohle, H. Zeller et al., “In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy,” American Journal of Pathology, vol. 154, no. 1, pp. 211–220, 1999. [50] T. Stallmach, G. Hebisch, P. Orban, and X. Lu¨, “Aberrant positioning of trophoblast and lymphocytes in the feto- maternal interface with pre-eclampsia,” Virchows Archiv, vol. 434, no. 3, pp. 207–211, 1999. [51] S. Di Paolo, P. Volpe, G. Grandaliano et al., “Increased placen- tal expression of tissue factor is associated with abnormal uter- ine and umbilical Doppler waveforms in severe preeclampsia with fetal growth restriction,” Journal of Nephrology, vol. 16, no. 5, pp. 650–657, 2003. [52] C. J. Lockwood, G. Krikun, and F. Schatz, “The decidua regulates hemostasis in human endometrium,” Seminars in Reproductive Endocrinology, vol. 17, no. 1, pp. 45–51, 1999. [53] C. J. Lockwood, G. Krikun, C. Papp et al., “The role of pro- gestationally regulated stromal cell tissue factor and type-1 plasminogen activator inhibitor (PAI-1) in endometrial he- mostasis and menstruation,” Annals of the New York Academy of Sciences, vol. 734, pp. 57–79, 1994. [54] J. Erlich, G. C. N. Parry, C. Fearns et al., “Tissue factor is required for uterine hemostasis and maintenance of the pla- cental labyrinth during gestation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 8138–8143, 1999. [55] C. A. Labarrere and W. P. Faulk, “Anchoring villi in human placental basal plate: lymphocytes, macrophages and coagula- tion,” Placenta, vol. 12, no. 2, pp. 173–182, 1991. [56] M. Uszynski, E. Ekanowska, W. Uszynski, and J. Kuczynski, “Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic ﬂuid and blood plasma: implications for the mechanism of amniotic ﬂuid embolism,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 95, no. 2, pp. 163–166, 2001. [57] C. J. Lockwood, R. Bach, A. Guha, X. Zhou, W. A. Miller, and Y. Nemerson, “Amniotic ﬂuid contains tissue factor, a potent initiator of coagulation,” American Journal of Obstetrics and Gynecology, vol. 165, no. 5 I, pp. 1335–1341, 1991. [58] P. Poredos and M. K. Jezovnik, “The role of inﬂammation in venous thromboembolism and the link between arterial and